Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Victhom Human Bionics Inc V.VHB



TSXV:VHB - Post by User

Post by BlueCitizenon Jun 18, 2009 11:14am
393 Views
Post# 16080861

Montreal Gazette - June 17, 2009

Montreal Gazette - June 17, 2009

Thought i'd share this one, looks interesting !

https://www.montrealgazette.com/Health/Bend+like+Victhom/1703242/story.html



In April, Victhom signed a joint-venture pact with Germany's Otto Bock HealthCare Gmbh to bring the Power Knee and other neuromodulation products, including Neurostep, to market. Otto Bock is a world leader in prosthetic and orthotic products.

Victhom is putting its Neurobionix Division into the joint venture, called Neurostream Technologies, for a 44.4-per-cent stake while Otto Bock is providing an initial $12.5 million for 55.6 per cent. Otto Bock will put up a total of $30 million over 30 months, which will be used for product development. Victhom is converting $18.35 million of debentures that are due next March into a new class of preferred shares.

Victhom spent $10.1 million on research last year, up 18.6 per cent from 2007, mostly because of work developing the commercial Power Knee and its Neurostep implantable technology. Research spending will be heavy again this year.

Both shareholders and debenture-holders, at separate meetings yesterday, approved the structural changes and financing.

"Both shareholders and debenture-holders are onside and we've created the foundation that will allow us to bring products from both the Biotronix and Neurobionics divisions to market and build a significant and profitable business," Rivard said.

<< Previous
Bullboard Posts
Next >>